Hengrui Pharma's 2026 ASCO portfolio covered gastrointestinal, breast, lung, urological, gynecological, and supportive-care oncology — 11 approved medicines, 10 pipeline candidates, and one Class 2 new drug (NMPA classification). Four results stand out for practicing oncologists and patients weighing where to receive next-line therapy: (1) the Phase II HORIZON-CRC01 study of the next-generation anti-HER2 antibody-drug conjugate trastuzumab rezetecan in HER2-positive, RAS/RAF wild-type metastatic colorectal cancer, which delivered a median progression-free survival of 5.5 months versus 2.8 months on standard-of-care chemotherapy; (2) the Phase III CARES-336 trial of camrelizumab plus rivoceranib combined with transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma, which pushed median PFS from 8.3 to 11.1 months and is being read as a new benchmark for systemic-plus-locoregional therapy; (3) the FUZUPRO study of fluzoparib combined with abiraterone acetate and prednisone in first-line metastatic castration-resistant prostate cancer, which lifted median radiographic PFS from 19.9 to 24.8 months; and (4) the perioperative muscle-invasive bladder cancer study of the anti-Nectin-4 ADC SHR-A2102 plus the PD-L1 inhibitor adebrelimab, which delivered a pathological complete response rate of 48.1% and a pathological downstaging rate of 59.3% — including in patients with renal dysfunction.
ASCO is the world's largest annual cancer-research meeting, and Chinese pharmaceutical research has grown from a peripheral presence in the early 2010s to a structural part of the program. At ASCO 2026, 94 Chinese research projects were selected for oral presentations, including 12 late-breaking abstracts — the third consecutive year of growth. Hengrui itself has now presented data at ASCO for 16 consecutive years.
What is different about 2026 is the maturity of the molecules. Hengrui's 91 studies this year are not first-in-human safety catalogues — they include late-line confirmatory Phase II studies, multiple Phase III randomized readouts, and combination regimens built around already-approved Chinese drugs being repositioned for new indications. For a foreign oncologist whose patient has run out of FDA- or EMA-approved options, several of these molecules are either investigational in their own country or accessible only through Chinese clinical-trial enrollment or the Hainan Boao Lecheng early-access pathway. We wrote about the Lecheng pathway in our March and April coverage of how international patients reach Chinese CAR-T and gene-therapy programs.
The four readouts below were chosen because each one is either immediately practice-changing for the disease it targets or because the molecule has a credible path to global registration within the next two to three years.
What was studied: Trastuzumab rezetecan — Hengrui's next-generation anti-HER2 antibody-drug conjugate — in HER2-positive, RAS and RAF wild-type metastatic colorectal cancer patients who had progressed after standard second-line therapy.
What was found: Median progression-free survival of 5.5 months on trastuzumab rezetecan versus 2.8 months on standard-of-care chemotherapy — roughly a doubling of PFS in a heavily pre-treated population where median PFS on standard chemo is typically under three months. The drug is a HER2-targeted ADC, a class that has transformed HER2-positive breast and gastric cancer over the past decade but has been slow to reach colorectal cancer because HER2 is amplified in only about 5% of CRC tumors.
Why it matters: The current third-line options for HER2-amplified, RAS/RAF wild-type colorectal cancer — trastuzumab plus lapatinib or trastuzumab plus tucatinib combinations — produce ORRs in the 30-45% range in retrospective series but have never had a randomized Phase III readout. HORIZON-CRC01's PFS data suggest an ADC may outperform the dual-antibody combinations. A Phase III confirmatory study would put trastuzumab rezetecan on a credible path to NMPA and eventual FDA approval.
For international patients with HER2-amplified colorectal cancer, trastuzumab rezetecan is the kind of drug that may be available through cross-border clinical-trial enrollment at major Chinese academic cancer centers — Shanghai GoBroad Cancer Hospital, Fudan Shanghai Cancer Center, or Sun Yat-sen University Cancer Center in Guangzhou — before it is available in their home country.
What was studied: The combination of camrelizumab (PD-1 inhibitor), rivoceranib (VEGFR2 tyrosine kinase inhibitor, also known as apatinib), and transarterial chemoembolization (TACE) versus TACE alone in patients with unresectable hepatocellular carcinoma (uHCC). This is the so-called "triplet" regimen that combines systemic immunotherapy, anti-angiogenic targeted therapy, and locoregional embolization.
What was found: Median progression-free survival of 11.1 months for the triplet versus 8.3 months for TACE alone (BICR-assessed per mRECIST) — a meaningful 2.8-month PFS extension in a disease where every month of PFS delay typically translates into meaningful transplant-eligibility windows and survival benefit.
Why it matters: The current standard for uHCC varies by region — atezolizumab plus bevacizumab (IMbrave150) is the global first-line standard, with durvalumab plus tremelimumab (HIMALAYA) as an alternative. In China, where atezolizumab was approved only in 2020 and remains expensive, the CARES-336 triplet represents a domestically producible, lower-cost regimen built around two drugs (camrelizumab and rivoceranib) that are already NMPA-approved and reimbursable. The data also position TACE as a partner rather than a competitor to systemic therapy — a pattern that may extend to other locoregional modalities.
For international patients — particularly those from Southeast Asia, the Middle East, and Africa, where HBV-driven hepatocellular carcinoma is the dominant liver-cancer presentation — the CARES-336 regimen is already available at major Chinese liver-cancer centers. Zhongshan Hospital, Fudan University in Shanghai is the global leader in HCC volume and runs one of the largest transplant-eligibility optimization programs in Asia.
What was studied: First-line fluzoparib (a PARP inhibitor) combined with abiraterone acetate and prednisone versus the standard abiraterone regimen alone in metastatic castration-resistant prostate cancer (mCRPC).
What was found: Median radiographic progression-free survival of 24.8 months for the combination versus 19.9 months for standard therapy — roughly a five-month rPFS extension in a first-line setting where abiraterone alone has historically delivered rPFS in the 16-20 month range.
Why it matters: PARP inhibitors in prostate cancer have been the biggest prostate-cancer story of the past five years. Two PARP inhibitors — olaparib and niraparib — are FDA-approved for HRR-mutated mCRPC, and one combination — olaparib plus abiraterone (PROpel) — is approved regardless of HRR status based on the PROpel trial. FUZUPRO enters that competitive space with a Chinese-developed PARP inhibitor and a 24.8-month rPFS readout that is competitive with PROpel's data. The fact that fluzoparib is already NMPA-approved and considerably less expensive than olaparib gives it a real cost-of-care advantage in markets that are price-sensitive.
For international patients with HRR-mutated or HRR-unselected mCRPC, fluzoparib plus abiraterone may be accessible at major Chinese urological-oncology centers. Fudan University Shanghai Cancer Center and Peking University First Hospital run some of the largest mCRPC programs in Asia and frequently accept international patient referrals for PARP-inhibitor therapy.
What was studied: Perioperative (neoadjuvant plus adjuvant) treatment of muscle-invasive bladder cancer with SHR-A2102 — Hengrui's anti-Nectin-4 antibody-drug conjugate, the same target as enfortumab vedotin (Padcev, the Astellas/Pfizer drug approved in the US) — combined with adebrelimab, a PD-L1 inhibitor developed by Hengrui. The study population included patients with renal dysfunction, a group typically excluded from cisplatin-based neoadjuvant chemotherapy.
What was found: Pathological complete response (pCR) rate of 48.1% and pathological downstaging rate of 59.3% in the perioperative setting — the deepest readout yet for an anti-Nectin-4 ADC plus checkpoint-inhibitor combination in bladder cancer, and particularly notable because it included cisplatin-ineligible patients.
Why it matters: Enfortumab vedotin plus pembrolizumab (the EV+pembro regimen) is the global standard for metastatic and now perioperative muscle-invasive bladder cancer, with EV-302 trial data showing dramatic survival benefit in metastatic disease. A Chinese-made anti-Nectin-4 ADC performing comparably in the perioperative setting — at a fraction of the cost of enfortumab vedotin — would be a meaningful addition to global bladder-cancer treatment. SHR-A2102 has not yet been outlicensed to a Western partner as of this writing, so access for international patients is currently via cross-border clinical-trial enrollment at Sun Yat-sen University Cancer Center and other participating sites.
For international patients with muscle-invasive bladder cancer — particularly those who are cisplatin-ineligible, a group that includes many older patients and patients with chronic kidney disease — SHR-A2102 plus adebrelimab may be an investigational option accessible through Chinese cancer centers.
The four Phase III readouts above are the headline-grabbing subset, but Hengrui's 91-study ASCO portfolio included additional late-stage results worth flagging:
Hengrui is not the only Chinese pharma company with a strong ASCO 2026 showing. Akeso (9926.HK) presented the AK138D1 HER3 ADC plus ivonescimab Phase Ib/II first-patient-dosed data we covered on June 17. Innovent, BeiGene, Hutchmed, and several smaller Chinese biotechs also presented. The aggregate of Chinese oral presentations has grown from a footnote to a structural part of the ASCO program.
The Hengrui ASCO 2026 readouts illustrate a pattern that is increasingly visible in Chinese oncology: late-stage randomized data, Chinese investigator leadership, and molecules that are globally competitive on either efficacy, cost, or both. For the four indications covered above — HER2+ colorectal cancer, unresectable hepatocellular carcinoma, first-line metastatic prostate cancer, and muscle-invasive bladder cancer — Chinese cancer centers now offer either approved or investigational access to drugs that are not yet available in most other countries.
The practical pathways for international patients are:
Each pathway has cost, language, and logistical considerations that we walk through in our detailed guides on accessing CAR-T therapy, gene therapy, and advanced oncology drugs in China. The short version: international oncology care in China is now a structural option for patients whose disease has outpaced what is available in their home country, and the Hengrui ASCO 2026 portfolio is one more data point in that direction.
If you are a patient, family member, or referring physician considering China for oncology care after a Hengrui ASCO 2026 readout (or any other Chinese oncology drug), the practical first step is a case-by-case assessment of which drug, which indication, and which hospital is the right fit. Hengrui's drugs are typically available at multiple sites — the question is which site has the most experience with your specific indication and which site's international-patient department is set up to handle your case smoothly.
The four readouts we covered above map to specific high-volume Chinese cancer centers:
For a broader view of which Chinese hospitals are strongest in which oncology indications, our hospital directory and tumor-type pages walk through the major academic cancer centers by disease area.
Hengrui Pharma's ASCO 2026 portfolio is one of the strongest single-company oncology data sets at any ASCO meeting in the past five years. The four Phase III readouts we unpacked — trastuzumab rezetecan in HER2+ colorectal cancer, camrelizumab + rivoceranib + TACE in unresectable HCC, fluzoparib + abiraterone in mCRPC, and SHR-A2102 + adebrelimab in muscle-invasive bladder cancer — each represent either a new treatment option or a new benchmark for an indication where the global standard has not advanced in years.
For international patients whose disease has progressed on Western-standard regimens, these drugs are increasingly accessible — either through NMPA-approved commercial pathways, cross-border clinical-trial enrollment, or the Hainan Boao Lecheng early-access program. As Chinese oncology drug development matures, the line between "investigational in China" and "globally available" continues to narrow, and ASCO 2026 is another data point that the narrowing is happening faster than most Western oncologists realize.
We will be tracking the Phase III confirmatory trials for each of these molecules and will update this site as new data emerges.
Need help accessing Hengrui drugs or other Chinese oncology therapies?
Our team can review your case, identify the right Chinese cancer center for your indication, and walk you through the clinical-trial, Lecheng early-access, or commercial-treatment pathways.
Request Free Case Review